OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, F...

Read more

Ysios Capital cierra su segundo fondo, Ysios BioFund II Innvierte, con un importe total de 126M EUR

by Ysios Capital

Ysios BioFund II Innvierte cuenta con una sólida base de inversores entre los que se encuentran: CDTI a través de su programa Innvierte, Fondo Europeo de Inversiones a través de InnovFin SME Ventur...

Read more

Aelix Therapeutics completes Series A funding of € 11.5 M ($ 12.7 M)

by Caixa Capital Risc

The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more
Subscribe to Directory
Write an Article

Highlight

3i closes second European CLO, Harvest V...

by 3i Group

3i Group plc (“3i” or “3i Group”), an international investor, ...

BioEnGas y Suma Capital colaboran para e...

by Suma Capital

La startup participada e impulsada por Enagás, BioEnGas, y la gestora...

Photos Stream